Bionovo, Inc. (BNVI.W)
--USD
--
-- (--)
$0.57
--
--
--
--
831,272
$1.15
$0.18
BNVI.W
About
Overall
| Beta: | 2.30 |
| Market Cap (Mil.): | $55.90 |
| Shares Outstanding (Mil.): | 107.52 |
| Annual Dividend: | 0.00 |
| Yield (%): | NA |
Financials
| BNVI.W | Industry | Sector | |
|---|---|---|---|
| P/E (TTM): | -- | 11.50 | 3.76 |
| EPS (TTM): | 6.26 | -- | -- |
| ROI: | -101.30 | 1.25 | 2.30 |
| ROE: | -104.64 | 2.09 | 2.82 |
Bionovo Q3 results
BIONOVO INC : * Third quarter loss per share $0.05 * Third quarter revenue $243,375 * Reuters Estimates third quarter earnings per share view $-0.05
Bionovo's sale of 10 mln shares priced at $2.50/shr
Oct 26 (Reuters) - Bionovo Inc said a public offering of 10 million shares of its common stock was priced at $2.50 a share.
CORRECTED - CORRECTED-Bionovo amends filing for $100 mln shelf offering
(Corrects headline and text after company clarified the filing was an amended one and part of the original shelf offering announced on June 25)
Bionovo names new CFO
June 28 (Reuters) - Drug development company Bionovo Inc. said it named Tom Chesterman as its chief financial officer, succeeding Jim Stapleton, effective July 9.
Bionovo files $100 mln shelf offering
June 26 (Reuters) - Bionovo Inc. said on Monday that it may periodically sell up to 24.9 million common shares to raise $100 million, and intends to use the proceeds for general corporate purposes, including funding clinical research and development.
Competitors
| Price | Change | |
|---|---|---|
| Pfizer Inc. (PFE.N) | $-- | -- |
| Novartis AG (NOVN.VX) | CHF57.10 | +0.30 |
| GlaxoSmithKline plc (GSK.L) | £1,201.00 | -17.50 |
| Sanofi-Aventis SA (SASY.PA) | €52.90 | +0.24 |
| Genentech, Inc. (DNA.N) | -- | -- |
| AstraZeneca plc (AZN.L) | £2,820.00 | +4.50 |
| Bristol Myers Squibb Co. (BMY.N) | $-- | -- |
| Bristol Myers Squibb Co. (BMY_p.N) | $-- | -- |
| Eli Lilly & Co. (LLY.N) | $-- | -- |
| Baxter International Inc. (BAX.N) | $-- | -- |
Earnings vs 
Estimates
Thomson Reuters is the world's largest international multimedia news agency, providing investing news, world news, business news, technology news, headline news, small business news, news alerts, personal finance, stock market, and mutual funds information available on Reuters.com, video, mobile, and interactive television platforms. Thomson Reuters journalists are subject to an Editorial Handbook which requires fair presentation and disclosure of relevant interests.
NYSE and AMEX quotes delayed by at least 20 minutes. Nasdaq delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.
